) recently reported a loss of 9 cents per share in the first
quarter of 2013, narrower than the Zacks Consensus Estimate of a
loss of 11 cents per share. The company had reported a loss of 8
cents in the year-ago quarter.
Revenues of $5.7 million in the first quarter of 2013 were
down 33.4% from a year ago. Revenues, however, beat the Zacks
Consensus Estimate of $3 million.
Quarter in Detail
The decline in ArQule's quarterly revenues was primarily due
to the reduction of $4.9 million from the company's AKIP
agreement with Daiichi Sankyo and $0.3 million from the ARQ 092
agreement with the latter. This was partially offset by a $0.5
million increase in revenue from the company's agreement with
Daiichi Sankyo related to the tivantinib program along with
increases from a one-time research project.
Research and development expenses were $8.2 million, down
12.1% from the year-ago quarter mainly due to lower outsourced
clinical and product development costs related to tivantinib and
pipeline programs. General and administrative expenses were $3.4
million, down 5.5% from the year-ago quarter.
We note that ArQule regained global rights for the development
and commercialization of compounds in Apr 2013, which are covered
under its AKT collaboration with Daiichi Sankyo Co., Ltd. ArQule
gained back its rights of the AKT program and also of ARQ 092
after Daiichi Sankyo decided to terminate the license and
2013 Outlook Reiterated
ArQule continues to expect revenues between $12 and $15
million in 2013. The Zacks Consensus Estimate of $15 million was
at the high-end of the guidance. ArQule anticipates net loss
between $28 million and $31 million in 2013. Loss per share is
estimated between 45 cents and 50 cents in 2013. The Zacks
Consensus estimate for 2013 hints at a loss of 49 cents.
ArQule will continue to focus on developing its oncology
candidate, tivantinib (ARQ 197), which has now entered into phase
III with the initiation of the METIV-HCC (MET-high patients with
tivantinib in HCC) trial in second-line HCC (hepatocellular
carcinoma or liver cancer).
The METIV-HCC trial, initiated in early 2013, is a controlled
study of previously treated patients with MET-high inoperable HCC
who will receive tivantinib as a single agent or placebo. The
trial is being conducted in collaboration with Daiichi Sankyo.
The company enrolled its first patient for this trial in the
first quarter of 2013.
ArQule currently carries a Zacks Rank #3 (Hold). Right now,
Onyx Pharmaceuticals, Inc
WuXi PharmaTech (Cayman) Inc.
), look well placed with a Zacks Rank #2 (Buy).
ARQULE INC (ARQL): Free Stock Analysis Report
FURIEX PHARMACT (FURX): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.